

Sc

FEB. 20. 2004 2:37PM


JCWSCS 23 FEB 2004

6508454166

DT02 Rec'd PCT/PTO 20 FEB 2004

NO. 8250 P. 1

PCT



Incyte Corporation
Legal Department
3180 Porter Drive
Palo Alto, CA 94304
Telephone: (650) 855-0555
Facsimile: (650) 845-4166
(650) 849-8886

Date: February 20, 2004
To: Office of Initial Patent Examination
Filing Receipt Corrections
Company: USPTO
Fax No.: 703-746-9195
Telephone No.:
From: Lisa McDill
Our Ref. No.: PF-0722 USN
Your Ref. No.: 10/031,915
Page(s): 14 , including cover sheet

Comments:

This facsimile is intended for the addressee only and may contain confidential information. If you have received this facsimile in error, please call us at 650.855.0555 immediately to arrange for its return.

Docket No.: PF-0722 USN

Certificate of Transmission

I hereby certify that this paper is being facsimile transmitted to the attention of Office of Initial Patent Examination, Filing Receipt Corrections, U.S. Patent and Trademark Office to Facsimile No. 703-746-9195 on February 20, 2004.

By: Printed: Lisa McDill**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**In re Application of: Hillman et al.Title: **CELL CYCLE AND PROLIFERATION PROTEINS**Serial No.: **10/031,915** Filing Date: **January 18, 2002**Examiner: **Carlson, K.** Group Art Unit: **1653**

Office of Initial Patent Examination
Filing Receipt Corrections
Fax No.: 703-746-9195

TRANSMITTAL FEE SHEET

Sir:

Transmitted herewith are the following for the above-identified application:

1. Request for Corrected Filing Receipt (2 pp.);
2. Official Filing Receipt with red-line markings to note changes (2 pp.);
3. Copy of 1st page of Published PCT, application no. PCT/US00/19948 (1 pg.); and
4. Copy of originally Executed Declaration and Power of Attorney (7 pp.).


The fee has been calculated as shown below.

 No additional Fee is required. Please charge Deposit Account No. **09-0108** in the amount of:**\$ 0**

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR §§ 1.16 and 1.17, or credit overpayment to Deposit Account No. 09-0108. A **duplicate copy of this sheet is enclosed**.

Respectfully submitted,

INCYTE CORPORATION

Date: February 20, 2004

Susan K. Sather
Reg. No. 44,316
Direct Dial Telephone: (650) 845-4646

Customer No.: 27904
3160 Porter Drive
Palo Alto, California 94304
Phone: (650) 855-0555
Fax: (650) 845-4166

119427

1

10/031,915

Docket No.: PF-0722 USN

Certificate of Transmission

I hereby certify that this paper is being facsimile transmitted to the attention of Office of Initial Patent Examination, Filing Receipt Corrections, U.S. Patent and Trademark Office to Facsimile No. 703-746-9195 on February 20, 2004.

By: Printed: Lisa McDill

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Hillman et al.Title: **CELL CYCLE AND PROLIFERATION PROTEINS**Serial No.: **10/031,915**

Filing Date:

January 18, 2002

Examiner: **Carlson, K.**

Group Art Unit:

1653

Office of Initial Patent Examination

Filing Receipt Corrections

Fax No.: 703-746-9195

REQUEST FOR A CORRECTED FILING RECEIPT

Sir:

Attached is a copy of the Official Filing Receipt (with red-line markings to note changes) received from the United States Patent and Trademark Office (USPTO) in the above application for which issuance of a corrected filing receipt is respectfully requested. Please make the correction as follows:

- Under the Section entitled, "Applicant(s)":
please replace "Chandra Awizu, Menlo Park, CA"
with -- Chandra S. Arvizu, Los Angeles, CA --; and

- Under the Section entitled, "Domestic Priority data as claimed by applicant":
please replace "This application is a 371 of PCT/US00/19948 07/21/2000"
with -- This application is a 371 of PCT/US00/19948 07/21/2000
which claims the benefit of 60/145,075 07/21/1999
and 60/153,129 09/08/1999
and 60/164,647 11/10/1999 --.

119424

1

10/031,915

Docket No.: PF-0722 USN

Applicants hereby request that the above corrections be entered based on the following enclosed documents:

1. A copy of the 1st page of the Published PCT, application no. PCT/US00/19948 (1 pg.); and
2. A copy of the originally Executed Declaration and Power of Attorney (7 pp.) *see page 6*.

Applicants believe that no fee is due with this paper. However, if the Commissioner determines that a fee is necessary, the Commissioner is hereby authorized to charge any additional fees associated with this communication or credit any overpayment to Deposit Account No. 09-0108.

Respectfully submitted,
INCYTE CORPORATION

Date: February 20, 2004

Susan K. Sather
Susan K. Sather
Reg. No. 44,316
Direct Dial Telephone: (650) 845-4646

Customer No.: 27904
3160 Porter Drive
Palo Alto, California 94304
Phone: (650) 855-0555
Fax: (650) 845-4166

119424

2

10/031,915

FEB. 20, 2004 2:38PM

6508454166

NO. 8250

P. 5
Page 1 of

APR 29 2003

COPY

Communication for Patent
Maintenance, Docket Number
USPTO-2003-000000000000

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY/DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
10/031,915	01/18/2002	1845	3936	PF-0722 USN		192	3

Incyte Genomics Inc
Legal Department
3160 Porter Drive
Palo Alto, CA 94304

CONFIRMATION NO. 1605
FILING RECEIPT

1605
"OC000000009872374"

Date Mailed: 04/23/2003

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Jennifer Hillman, Mountain View, CA;
Preeti Lal, Santa Clara, CA;
Y Tom Tang, San Jose, CA;
Henry Yue, Sunnyvale, CA;
Janice Au-Young, Brisbane, CA;
Olga Bandman, Mountain View, CA;
Yalda Azimzai, Castro Valley, CA;
Junming Yang, San Jose, CA;
Dyung Aina M Lu, San Jose, CA;
Mariah R Baughn, San Leandro, CA;
Chandra Awizu, Menlo Park, CA; *Chandra S. Arvizu, Menlo Park, CA* --
Puri Shah, San Jose, CA;

Domestic Priority data as claimed by applicant

-- This application is a 371 of PCT/US00/19948 07/21/2000
which claims the benefit of 60/145,075 07/21/1999

Foreign Applications 60/163,129 09/08/1999
and 60/164,647 11/10/1999 --

Projected Publication Date: None, application is not eligible for pre-grant publication

Non-Publication Request: No

Early Publication Request: No

Title

Cell cycle and proliferation proteins

Preliminary Class

435

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

COPY

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
1 February 2001 (01.02.2001)

PCT

(10) International Publication Number
WO 01/07471 A2(51) International Patent Classification²: C07K 14/00

[CN/US]; 7125 Bark Lane, San Jose, CA 95129 (US). LU, Dyoung, Anna, M. [US/US]; 55 Park Belmont Place, San Jose, CA 95136 (US). BAUGHN, Mariah, R. [US/US]; 14244 Sandigo Road, San Leandro, CA 94577 (US). PATTERSON, Chandra [US/US]; 490 Sherwood Way #1, Menlo Park, CA 94025 (US). SHAH, Purvi [IN/US]; 1608 Queen Charlotte Drive #5, Sunnyvale, CA 94087 (US).

(21) International Application Number: PCT/US00/19948

(22) International Filing Date: 21 July 2000 (21.07.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/145,075 21 July 1999 (21.07.1999) US
60/153,129 8 September 1999 (08.09.1999) US
60/164,647 10 November 1999 (10.11.1999) US

(74) Agents: HAMLET-COX, Diana et al.; Incyte Genomics, Inc., 3160 Porter Drive, Palo Alto, CA 94304 (US).

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier applications:

US 60/145,075 (CIP)
Filed on 21 July 1999 (21.07.1999)
US 60/153,129 (CIP)
Filed on 8 September 1999 (08.09.1999)
US 60/164,647 (CIP)
Filed on 10 November 1999 (10.11.1999)

(81) Designated States (national): AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— Without international search report and to be republished upon receipt of that report.

(48) Date of publication of this corrected version:

17 May 2001

(15) Information about Correction:

see PCT Gazette No. 20/2001 of 17 May 2001, Section II

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

A2

WO 01/07471

(54) Title: CELL CYCLE AND PROLIFERATION PROTEINS

(57) Abstract: The invention provides human cell cycle and proliferation proteins (CCYPR) and polynucleotides which identify and encode CCYPR. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for